Placebo for crohn disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Mar 2018: Trial registered, NCT03466411
  2. 13 Apr 2018: Trial started, NCT03466411

The trials

NCT03466411: A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

State
Under way
Phase
Phase 2 and Phase 3
People
1,409 taking part
Started
13 Apr 2018
Primary completion
20 Oct 2023
Arms
Phase 2 (GALAXI 1): Group 5 (Placebo/Ustekinumab), Phase 3 (GALAXI 2 and 3): Group 4 (Placebo/Ustekinumab)
Results
Posted on the registry
  1. 15 Mar 2018: Trial registered
  2. 13 Apr 2018: Trial started
  3. 7 May 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.